RayzeBio (RYZB)

Cash burn rate (est.)	Burn method: Operating income	Burn method: FCF (opex + capex)
Cash on hand (at last report)	252.30 mm	252.30 mm
Cash burn (monthly)	7.22 mm	167.00 k
Cash used (since last report)	106.93 mm	2.47 mm
Cash remaining	145.38 mm	249.83 mm
Runway (months of cash)	20.1	1496.0

Beta Read what these cash burn values mean

Financial data from RayzeBio earnings reports.

Institutional ownership, Q3 2023

RYZB institutional ownership history Ownership history

97.1% owned by funds/institutions

13F holders	Current	Change
Total holders	67	NEW
Opened positions	67	NEW
Closed positions	0
Increased positions	0
Reduced positions	0

13F shares	Current	Prev Q	Change
Total value	1.19 tn	0.00	NEW
Total shares	58.17 mm	0.00	NEW
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Viking Global Investors	6.64 mm	$147.47 bn	NEW
venBio Partners	5.16 mm	$114.51 bn	NEW
Versant Venture Management	5.16 mm	$114.51 bn	NEW
VR Adviser	4.02 mm	$89.17 bn	NEW
Venrock Healthcare Capital Partners III	4.02 mm	$88.41 mm	NEW
Wellington Management	3.88 mm	$84.49 bn	NEW
Orbimed Advisors	2.62 mm	$58.23 bn	NEW
Sofinnova Investments	2.42 mm	$53.71 bn	NEW
Redmile	1.86 mm	$41.24 bn	NEW
Samsara BioCapital	1.85 mm	$40.98 bn	NEW

Largest transactions	Shares	Bought/sold	Change
Viking Global Investors	6.64 mm	+6.64 mm	NEW
venBio Partners	5.16 mm	+5.16 mm	NEW
Versant Venture Management	5.16 mm	+5.16 mm	NEW
VR Adviser	4.02 mm	+4.02 mm	NEW
Venrock Healthcare Capital Partners III	4.02 mm	+4.02 mm	NEW
Wellington Management	3.88 mm	+3.88 mm	NEW
Orbimed Advisors	2.62 mm	+2.62 mm	NEW
Sofinnova Investments	2.42 mm	+2.42 mm	NEW
Redmile	1.86 mm	+1.86 mm	NEW
Samsara BioCapital	1.85 mm	+1.85 mm	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

RYZB insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
22 Jan 24	Susan Moran	Common Stock	Option exercise	Acquire M	No	No	3.24	30,875	100.04 k	322,647
22 Jan 24	Susan Moran	Employee Stock Option Common Stock	Option exercise	Dispose M	No	No	3.24	30,875	100.04 k	60,757
17 Nov 23	Susan Moran	Stock Option Common Stock	Grant	Acquire A	No	No	22.72	164,000	3.73 mm	164,000
17 Nov 23	Kenneth Song	Stock Option Common Stock	Grant	Acquire A	Yes	No	22.72	480,000	10.91 mm	480,000
17 Nov 23	Maha Katabi	Stock Option Common Stock	Grant	Acquire A	No	No	22.72	18,235	414.30 k	18,235
17 Nov 23	Arvind Kush	Stock Option Common Stock	Grant	Acquire A	No	No	22.72	164,000	3.73 mm	164,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

Axonis Therapeutics Announces $115 Million Series A Financing

30 Oct 24

-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024